Transcranial magnetic stimulation: Emerging biomarkers and novel therapeutics in Alzheimer's disease

Research output: Contribution to journalReview article

Abstract

Alzheimer's disease (AD) is one of the most devastating conditions affecting elderly in Western World. Unfortunately, there are no effective treatments, and patients diagnosed with AD face an uncertain future, caused by the current inability to predict the course of the disease. This is mainly due to the poor comprehension of AD pathophysiology and of patients’ clinical heterogeneity. In recent years, several evidences supported the concept that loss of synaptic density could be an early event and precede neuronal degeneration, suggesting that the impairment of synaptic transmission should play a key role in the pathogenesis of different forms of dementia, including AD, frontotemporal dementia and Lewy body dementia. Despite this emerging background it has not been possible to quantify synaptic functioning (or dysfunction) directly in vivo in AD patients. Transcranial magnetic stimulation (TMS) has been recently introduced as a novel approach able to identify the early signatures of synaptic dysfunction characterizing the different forms of AD. We review the novel emerging neurophysiological signatures of AD and how this information may be used as biomarkers for differential diagnosis, disease progression and response to therapy. Finally, we also consider novel therapeutic approaches based on the clinical use of repetitive TMS.

Original languageEnglish
Article number134355
JournalNeuroscience Letters
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Transcranial Magnetic Stimulation
Alzheimer Disease
Biomarkers
Therapeutics
Lewy Body Disease
Frontotemporal Dementia
Western World
Synaptic Transmission
Dementia
Disease Progression
Differential Diagnosis

Keywords

  • Alzheimer's disease
  • Biomarkers
  • TMS
  • Transcranial magnetic stimulation

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

@article{bba09f8830ad40c2b6d38a08d071fcb5,
title = "Transcranial magnetic stimulation: Emerging biomarkers and novel therapeutics in Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is one of the most devastating conditions affecting elderly in Western World. Unfortunately, there are no effective treatments, and patients diagnosed with AD face an uncertain future, caused by the current inability to predict the course of the disease. This is mainly due to the poor comprehension of AD pathophysiology and of patients’ clinical heterogeneity. In recent years, several evidences supported the concept that loss of synaptic density could be an early event and precede neuronal degeneration, suggesting that the impairment of synaptic transmission should play a key role in the pathogenesis of different forms of dementia, including AD, frontotemporal dementia and Lewy body dementia. Despite this emerging background it has not been possible to quantify synaptic functioning (or dysfunction) directly in vivo in AD patients. Transcranial magnetic stimulation (TMS) has been recently introduced as a novel approach able to identify the early signatures of synaptic dysfunction characterizing the different forms of AD. We review the novel emerging neurophysiological signatures of AD and how this information may be used as biomarkers for differential diagnosis, disease progression and response to therapy. Finally, we also consider novel therapeutic approaches based on the clinical use of repetitive TMS.",
keywords = "Alzheimer's disease, Biomarkers, TMS, Transcranial magnetic stimulation",
author = "Giacomo Koch and Alessandro Martorana and Carlo Caltagirone",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.neulet.2019.134355",
language = "English",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Transcranial magnetic stimulation

T2 - Emerging biomarkers and novel therapeutics in Alzheimer's disease

AU - Koch, Giacomo

AU - Martorana, Alessandro

AU - Caltagirone, Carlo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Alzheimer's disease (AD) is one of the most devastating conditions affecting elderly in Western World. Unfortunately, there are no effective treatments, and patients diagnosed with AD face an uncertain future, caused by the current inability to predict the course of the disease. This is mainly due to the poor comprehension of AD pathophysiology and of patients’ clinical heterogeneity. In recent years, several evidences supported the concept that loss of synaptic density could be an early event and precede neuronal degeneration, suggesting that the impairment of synaptic transmission should play a key role in the pathogenesis of different forms of dementia, including AD, frontotemporal dementia and Lewy body dementia. Despite this emerging background it has not been possible to quantify synaptic functioning (or dysfunction) directly in vivo in AD patients. Transcranial magnetic stimulation (TMS) has been recently introduced as a novel approach able to identify the early signatures of synaptic dysfunction characterizing the different forms of AD. We review the novel emerging neurophysiological signatures of AD and how this information may be used as biomarkers for differential diagnosis, disease progression and response to therapy. Finally, we also consider novel therapeutic approaches based on the clinical use of repetitive TMS.

AB - Alzheimer's disease (AD) is one of the most devastating conditions affecting elderly in Western World. Unfortunately, there are no effective treatments, and patients diagnosed with AD face an uncertain future, caused by the current inability to predict the course of the disease. This is mainly due to the poor comprehension of AD pathophysiology and of patients’ clinical heterogeneity. In recent years, several evidences supported the concept that loss of synaptic density could be an early event and precede neuronal degeneration, suggesting that the impairment of synaptic transmission should play a key role in the pathogenesis of different forms of dementia, including AD, frontotemporal dementia and Lewy body dementia. Despite this emerging background it has not been possible to quantify synaptic functioning (or dysfunction) directly in vivo in AD patients. Transcranial magnetic stimulation (TMS) has been recently introduced as a novel approach able to identify the early signatures of synaptic dysfunction characterizing the different forms of AD. We review the novel emerging neurophysiological signatures of AD and how this information may be used as biomarkers for differential diagnosis, disease progression and response to therapy. Finally, we also consider novel therapeutic approaches based on the clinical use of repetitive TMS.

KW - Alzheimer's disease

KW - Biomarkers

KW - TMS

KW - Transcranial magnetic stimulation

UR - http://www.scopus.com/inward/record.url?scp=85068525921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068525921&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2019.134355

DO - 10.1016/j.neulet.2019.134355

M3 - Review article

AN - SCOPUS:85068525921

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

M1 - 134355

ER -